Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201
Peter J O’Dwyer, Patrick J. Flynn, Audrey E. Kam, Nicholas J. Petrelli et al.
Journal
The Oncologist
Topics
Colorectal Cancer Surgical Treatments
article
Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201
Peter J O’Dwyer, Patrick J. Flynn, Audrey E. Kam, Nicholas J. Petrelli, Al B. Benson, Mary F. Mulcahy, Fengmin Zhao, David F Cella, Kendrith M. Rowland, Neal J. Meropol, Robert J. Mayer, Lee Hartner, Robert B. Diasio, Frank A. Sinicrope, Paul J. Catalano, Stanley R. Hamilton, Bruce J. Giantonio, Wei Song, Robert P. Whitehead
article en
Abstract
No abstract available for this paper.
Publication Tag
The OncologistVol. 31(1)
Institutions
Northwestern University (US), Rush University Medical Center (US), Carle Foundation Hospital (US), Abbott Northwestern Hospital (US), Massachusetts General Hospital (US), Women's Cancer Center of Nevada (US), Northwestern University (PH), City of Hope (US), Medical Oncology Hematology Consultants (US), Dana-Farber Cancer Institute (US), Pottstown Medical Specialists (United States) (US), Mayo Clinic in Arizona (US), Las Vegas Institute (US), Dana-Farber/Harvard Cancer Center (US), Hematology Oncology Associates (US), Northwestern Medicine (US), Center for Cancer Research (US), Flatiron Health (United States) (US), Comprehensive Cancer Centers of Nevada (US), UCSF Helen Diller Family Comprehensive Cancer Center (US), Case Comprehensive Cancer Center, Case Western Reserve University (US), University of Pennsylvania (US)
Funders
American College of Radiology Imaging Network, ECOG-ACRIN Cancer Research Group, National Institutes of Health, National Cancer Institute